70797-11-4

Yellow crystals, melting point 213-215°C (decomposition).
Cefpiramide Sodium (Cefpiramide Sodium): C25H23N8O7S2Na. [74849-93-7]. White to yellowish-white crystalline powder, odorless, bitter. Very soluble in dimethylformamide, freely soluble in water, slightly soluble in methanol, very slightly soluble in ethanol, practically insoluble in chloroform, acetone, tetrahydrofuran, acetonitrile, or n-hexane.

Antibacterial.

ChEBI: A third-generation cephalosporin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl and (R)-2-{[(4-hydroxy-6-methylpyridin-3-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectiv ly, of the cephem skeleton. It has a broad spectrum of antibacterial activity.

A semisynthetic parenteral cephalosporin. It exhibits a broad range of activity, which includes Ps. aeruginosa, though the overall activity is rather modest. It is moderately stable to most β-lactamases but less so than ceftazidime or cefpirome.
In volunteers given 0.5 or 1 g by intravenous bolus, the mean plasma concentration shortly after injection was around 150 or 300 mg/L, respectively. There was no accumulation when the same doses were repeated every 12 h for 11 doses. It is highly bound to plasma protein (c. 95%). The mean plasma half-life is around 5 h. Less than one-quarter of the dose appears in the urine over 24 h; the rest is excreted in bile and high concentrations are found in feces. Renal impairment has little effect on elimination in patients with normal liver function.
Diarrhea may be associated with marked suppression of gut flora resulting from biliary excretion of the drug. The molecule includes a C-3 methylthiotetrazole side chain and side effects associated with that substituent are to be expected.
It is available in Japan.

β-lactam